Impact of medication therapy discontinuation on glycemic control and health care utilization in patients with diabetes
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
Merck & Co., Inc.
|
| Funding Years:
2013-2014 |
| |
|
The goals of the proposed study are to evaluate the frequency of medication therapy discontinuation among adults with diabetes prescribed two oral antihyperglycemic agents and to identify patient and physician factors associated with therapy discontinuation. |
|
|
|
Treatment Decisions and Resource Utilization During Antiviral Therapy For Chronic Hepatitis C in a Large Health Maintenance Organization
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
Gilead Sciences, Inc.
|
|
|
| |
|
|
|
|
|
A Descriptive Evaluation of Risk Evaluation and Mitigation Strategies Knowledge Management at Kaiser Permanente Southern California
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
Bristol-Myers Squibb
|
|
|
| |
|
|
|
|
|
A Novel Centralized Gout Clinic for Chronic Gout Management
|
|
Craig Cheetham, PharmD, MS, Site Principal Investigator
|
| |
|
Funding source:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
| Funding Years:
2012-2014 |
| |
|
Comparing the effectiveness of a novel pharmacy-based CGC that incorporates protocol-driven care with usual care in the treatment of chronic gout and to compare the relative treatment adherence and tolerability of allopurinol administered through the CGC. |
|
|
|
Evaluation of Hepatitis C Treatments and Associated Outcomes in Chronic HCV Patients
|
|
Craig Cheetham, PharmD, MS, Principal Investigator
|
| |
|
Funding source:
Bristol-Myers Squibb
|
| Funding Years:
2013-2014 |
| |
|
|
|
|
|
Cardiovascular Risk in Patients with Rheumatoid Arthritis in a Managed Care Setting
|
|
Craig Cheetham, PharmD, MS, Principal Investigator
|
| |
|
Funding source:
Bristol-Myers Squibb
|
| Funding Years:
2012-2013 |
| |
|
Evaluate factors associated with CV events in an RA population and compare this to the age and gender matched non-RA population. |
|
|
|
Cardiovascular and Prostatic Safety of Testosterone Therapy in Aging Males
|
|
Craig Cheetham, PharmD, MS, Principal Investigator
|
| |
|
Funding source:
National Institute on Aging (NIA)
|
| Funding Years:
2012-2014 |
| |
|
Determine the risk of cardiovascular events associated with the use of testosterone replacement therapy, and test the hypothesis that the risk of benign and malignant prostate disease associated with the use of testosterone replacement therapy is greater than expecte4d for men of similar underlying risk. |
|
|
|
Real–World Study to Identify Clinical Characteristics and Healthcare Resource Utilization of Patients with Refractory Chronic Gout
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
Savient Pharmaceutical, Inc.
|
|
|
| |
|
|
|
|
|
Antiviral Medication Use During Pregnancy and Adverse Pregnancy Outcomes
|
|
Craig Cheetham, PharmD, MS, Principal Investigator
|
| |
|
Funding source:
No Sponsor
|
|
|
| |
|
|
|
|
|
Mini Sentinel: Dabigatran
|
|
Craig Cheetham, PharmD, MS, Site Principal Investigator
|
| |
|
Funding source:
Food and Drug Administration (FDA)
|
|
|
| |
|
|
|
|
|
Systemic sulfonamide use during pregnancy and the risk of selected congenital anomalies - MEPREP
|
|
Craig Cheetham, PharmD, MS, Site Principal Investigator
|
| |
|
Funding source:
Food and Drug Administration (FDA)
|
| Funding Years:
2011-2013 |
| |
|
Evaluate birth-defects associated with the administration of sulfonamides during the first trimester. |
|
|
|
Extracorporeal Shock Wave Lithotripsy (ESWL): Long Term Safety and Outcomes in Kaiser Permanente Southern California
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
Pharmacy Analytical Service
|
|
|
| |
|
|
|
|
|
Detection and Analysis of Adverse Events related to Regulated Products in Automated Healthcare Data. Efforts to Develop the Sentinel Initiative
|
|
Craig Cheetham, PharmD, MS, Site Principal Investigator
|
| |
|
Funding source:
Food and Drug Administration (FDA)
|
|
|
| |
|
|
|
|
|
Serious Adverse Event Consortium Phase II
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
International Serious Adverse Event Consortium
|
|
|
| |
|
|
|
|
|
What are the Healthcare Costs and Consequences of Delaying or Not Picking Up Antibiotic Prescriptions in the Outpatient Setting
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
University of Southern California (USC), Los Angeles
|
|
|
| |
|
|
|
|
|
The Automated Roussel Uclaf Causality Assessment Method (RUCAM): An Electronic Causality Assessment Tool For Drug-Induced Liver Injury
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
United BioSource Corporation
|
|
|
| |
|
|
|
|
|
A Descriptive Liver Safety Analysis at Kaiser Permanente Southern California
|
|
Craig Cheetham, PharmD, MS, Co-Investigator
|
| |
|
Funding source:
No Sponsor
|
|
|
| |
|
|
|
|
|
Fetal Risks of Immunosuppressive Drugs Used in Autoimmune Disease
|
|
Craig Cheetham, PharmD, MS, Site Principal Investigator
|
| |
|
Funding source:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
| Funding Years:
2008-2012 |
| |
|
|
|
|
|
HMO Research Network CERT III - ADR Surveillance
|
|
Craig Cheetham, PharmD, MS, Principal Investigator
|
| |
|
Funding source:
Agency for Healthcare Research and Quality (AHRQ)
|
|
|
| |
|
|
|
|
|
HMO Research Network CERT III - Infrastructure
|
|
Craig Cheetham, PharmD, MS, Principal Investigator
|
| |
|
Funding source:
Harvard Pilgrim Health Care, Inc
|
|
|
| |
|
|
|
|
|
|
